Glaukos Corporation to Release Second Quarter 2018 Financial Results after Market Close on August 2
July 19 2018 - 07:00AM
Business Wire
Conference Call and Webcast Scheduled for 1:30
p.m. PDT
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical
technology and pharmaceutical company focused on the development
and commercialization of novel surgical devices and sustained
pharmaceutical therapies designed to transform the treatment of
glaucoma, plans to release second quarter 2018 financial results
after the market close on Thursday, August 2, 2018. The company’s
management will discuss the results during a conference call and
simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on August 2,
2018.
A link to the live webcast will be available on the company’s
website at http://investors.glaukos.com. To participate in the
conference call, please dial 866-393-4306 (U.S.) or 734-385-2616
(International) and enter Conference ID 7791765. A replay will be
archived on the company’s website following completion of the
call.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology
and pharmaceutical company focused on the development and
commercialization of novel surgical devices and sustained
pharmaceutical therapies designed to transform the treatment of
glaucoma, one of the world’s leading causes of blindness. The
company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to
revolutionize the traditional glaucoma treatment and management
paradigm. Glaukos launched the iStent® Trabecular Micro-Bypass
Stent, its first MIGS device, in the United States in July 2012 and
is leveraging its platform technology to build a comprehensive and
proprietary portfolio of micro-scale injectable therapies designed
to address the complete range of glaucoma disease states and
progression. The company believes the iStent inject, which measures
0.36 mm long and 0.23 mm wide, is the smallest medical device ever
approved by the FDA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180719005179/en/
Glaukos CorporationChris LewisDirector, Investor Relations,
Corporate Strategy & Development(949)
481-0510clewis@glaukos.com
Glaukos (NYSE:GKOS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Glaukos (NYSE:GKOS)
Historical Stock Chart
From Mar 2023 to Mar 2024